The company we're looking at seems to be doing well, but let's not get too excited just yet. Here’s a simpler look at what’s happening: What the Charts Say : The RSI, which is a fancy way of saying how fast the stock price is moving, is at 83. This is usually a sign that the stock price might go down soon. In the past, when this number got really high, the stock...
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders,...
Based on 7 Wall Street analysts offering 12 month price targets for Sangamo Biosciences in the last 3 months. The average price target is $8.20 with a high forecast of $16.00 and a low forecast of $1.50. The average price target represents a 443.05% change from the last price of $1.51.
Sangamo therapeutics, defensive sector has very much underperformed the overall market. Following channel for almost 20 years. Bullish candle on the May close, am watching for follow through. Holding trendline brings the .236 in play.
As noted on the chart, SGMO is displaying a possible rebound play. It has the potential for 20-30 upside. Good Luck...
As long as this company has more than 300 employees, I am still its long-term investor using writing its options to generate additional income.
Bat pattern on SGMO 15 mins. Target 1: 12.62
Down-sloping resistance along horizontal support. Daily hidden bullish divergence on the MACD and RSI 4hr classic bullish divergence on the MACD At 0.618 retrace Stop = Below horizontal support 1st Target = 0.382 extension/resistance 2nd Target = 0.618 extension/resistance
SGMO has retested C and possible ready to move up. Looks almost like a flag, but the flag is getting a bit heavy and is over 3 weeks in formation. SGMO had a big move up, and I guess sometimes if you play, you pay in this market )o: I thought there was a gap overhead, but there is a long wick on top of the green candle. I guess it depends on your definition...
Pay for your much needed therapy this week with your profits from a continuation on a SGMOtheraputics breakout. If you missed area of value as outlined by my post last friday we could still be in a good buy position for continuation of this breakout. Safe trading!
SGMO is in the gene editing space. Nice setup as it successfully tested the breakout spot and found support. Now launching higher today off key moving averages. CRSP reports earnings this week so we could see a positive catalyst. I took some May $15 calls today.
$SGMO has been correcting its 100% surge higher, I believe I have found enough evidence to suggest the $SGMO pullback has completed and represents a great buy opportunity: 1) +1 year long resistance is acting as support 2) reclaiming of the aVWAP from the bottom for the first time in 8 days 3) holding the 50 day EMA 4) consolidation occurring at the 50%...
grabbed commons with the break in the DT could be too early so starting position is small
on a break out, i will get in long. Heard great things about this company's fundamentals. I would like to see it confrimed.
Entry price : 15.02 Fundamentals : - Sector: Medical - Biotech - EPS % Chg (Last Qtr): 95% - EPS % Chg (Previous Qtr): 1% - 3 Year EPS Growth Rate: 0% - EPS Est % Chg (Current Yr): 0% - Sales % Chg (Last Qtr): 163% - Sales % Chg (Previous Qtr): 23% - 3-Year Sales Growth Rate: 54% - Annual Pre -Tax Margin: -93.2%
any pullbacks are additional short-term trades
Dragon pattern @ horizontal support Daily and 4hr hidden bullish divergence on the MACD and RSI Stop = Below 2nd support 1st Target = Resistance/previous high 2nd Target = 1.618 fib extension
support held past few weeks around $15.70. declining volume on sell-off. owns many patents and has deals to bring many CRISPR style medications through development testing and sales. strong revenue growth in a growing and increasingly accepted medical field. potential breakout target of $29. Biotech stocks are high risk as they depend on experiment success or...